Hitachi Chemical Advanced Therapeutics Solutions (HCATS) has signed a three-year clinical manufacturing agreement with GSK. Under the agreement, HCATS will manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials.    NY-ESO is expressed across a variety of tumors including sarcomas, melanoma, multiple myeloma, bladder cancer, non-small cell lung cancer, ovarian cancer and gastro-intestinal cancers. HCATS is a US subsidiary of Hitachi Che...